Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | MicrobiomeTrials← Back to trialsNCT07609940
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-07-15Est. Completion: 2027-10-11
Enrollment target: 30 participants Locations- Berenson Cancer Center, Los Angeles, California, United States
- Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
- Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
Other microbiome trials you might be interested in
Relapsed/Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evalua…
Wuhu, ChinaEst. completion Oct 20, 2026
Relapsed Refractory Multiple Myeloma (RRMM)
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called …
Randwick, AustraliaEst. completion Sep 30, 2033